Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prediction of anticoagulant effect of dabigatran and rivaroxaban in atrial fibrillation
NL-OMON37535Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dabigatran and rivaroxaban in Atrial fibrillation (AFib) (2 cohorts), sponsored by Maastricht University Medical Center+. Primary endpoints: Thrombin generation, Variation in anticoagulant effect between patients and 4 more. Started Nov 2012; status: active, not recruiting.
02
Drugs
dabigatranrivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON37535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37535.